The biological players involved in angiogenesis are only partially defined. Here, we report that endothelial cells (ECs) express a novel isoform of the cell-surface adhesion molecule L1CAM, termed L1-DTM. The splicing factor NOVA2, which binds directly to L1CAM pre-mRNA, is necessary and sufficient for the skipping of L1CAM transmembrane domain in ECs, leading to the release of soluble L1-DTM. The latter exerts high angiogenic function through both autocrine and paracrine activities. Mechanistically, L1-DTM-induced angiogenesis requires fibroblast growth factor receptor-1 signaling, implying a crosstalk between the two molecules. NOVA2 and L1-DTM are overexpressed in the vasculature of ovarian cancer, where L1-DTM levels correlate with tumor vascularization, supporting the involvement of NOVA2-mediated L1-DTM production in tumor angiogenesis. Finally, high NOVA2 expression is associated with poor outcome in ovarian cancer patients. Our results point to L1-DTM as a novel, EC-derived angiogenic factor which may represent a target for innovative antiangiogenic therapies.
A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing / Angiolini, F., Belloni, E., Giordano, M., Campioni, M., Forneris, F., Paronetto, M.p., Lupia, M., Brandas, C., Pradella, D., Di Matteo, A., Giampietro, C., Jodice, G., Luise, C., Bertalot, G., Freddi, S., Malinverno, M., Irimia, M., Moulton, J.d., Summerton, J., Chiapparino, A., et al.. - In: ELIFE. - ISSN 2050-084X. - STAMPA. - 8:(2019), pp. e4430501-e4430527. [10.7554/eLife.44305.001]
A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing
Bertalot G;
2019-01-01
Abstract
The biological players involved in angiogenesis are only partially defined. Here, we report that endothelial cells (ECs) express a novel isoform of the cell-surface adhesion molecule L1CAM, termed L1-DTM. The splicing factor NOVA2, which binds directly to L1CAM pre-mRNA, is necessary and sufficient for the skipping of L1CAM transmembrane domain in ECs, leading to the release of soluble L1-DTM. The latter exerts high angiogenic function through both autocrine and paracrine activities. Mechanistically, L1-DTM-induced angiogenesis requires fibroblast growth factor receptor-1 signaling, implying a crosstalk between the two molecules. NOVA2 and L1-DTM are overexpressed in the vasculature of ovarian cancer, where L1-DTM levels correlate with tumor vascularization, supporting the involvement of NOVA2-mediated L1-DTM production in tumor angiogenesis. Finally, high NOVA2 expression is associated with poor outcome in ovarian cancer patients. Our results point to L1-DTM as a novel, EC-derived angiogenic factor which may represent a target for innovative antiangiogenic therapies.| File | Dimensione | Formato | |
|---|---|---|---|
|
Angiolini.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
1.79 MB
Formato
Adobe PDF
|
1.79 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione



